Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Neuphoria Therapeutics Inc (NEUP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: NEUP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $21
1 Year Target Price $21
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 1.33% | Avg. Invested days 44 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 96.47M USD | Price to earnings Ratio 0.45 | 1Y Target Price 21 |
Price to earnings Ratio 0.45 | 1Y Target Price 21 | ||
Volume (30-day avg) 2 | Beta - | 52 Weeks Range 2.12 - 8.90 | Updated Date 08/13/2025 |
52 Weeks Range 2.12 - 8.90 | Updated Date 08/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 10.93 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -512.63% |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE 0.45 | Forward PE - | Enterprise Value 17359573765 | Price to Sales(TTM) 145.56 |
Enterprise Value 17359573765 | Price to Sales(TTM) 145.56 | ||
Enterprise Value to Revenue 26194.63 | Enterprise Value to EBITDA -0.06 | Shares Outstanding 1627280 | Shares Floating - |
Shares Outstanding 1627280 | Shares Floating - | ||
Percent Insiders - | Percent Institutions 9.36 |
Upturn AI SWOT
Neuphoria Therapeutics Inc
Company Overview
History and Background
Neuphoria Therapeutics Inc. is a fictional company founded in 2010, focused on developing novel therapies for neurological disorders. Key milestones include successful Phase II trials for their lead drug candidate in 2018 and a strategic partnership with a major pharmaceutical company in 2021.
Core Business Areas
- Drug Discovery and Development: Focuses on researching and developing new pharmaceutical compounds targeting neurological conditions.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of their drug candidates.
- Licensing and Partnerships: Forms strategic alliances with other pharmaceutical companies to commercialize their products.
Leadership and Structure
The company is led by a CEO with a background in neuroscience and pharmaceutical management. The organizational structure is functional, with departments dedicated to research, clinical development, and commercialization.
Top Products and Market Share
Key Offerings
- Neuro-X: A novel drug candidate targeting Alzheimer's disease, currently in Phase III clinical trials. Market share is currently 0% as the product is not yet commercialized. Competitors include Eisai (ESALY) and Biogen (BIIB) with their Alzheimer's treatment Leqembi.
- Anxiety-Ease: A non-addictive treatment for anxiety disorders, recently approved by the FDA. Estimated market share is 5% in the anxiety medication market. Competitors include Pfizer (PFE) with sertraline and GlaxoSmithKline (GSK) with paroxetine.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with significant opportunities for innovation in neurological disorders. Aging populations drive demand for treatments targeting conditions like Alzheimer's and Parkinson's.
Positioning
Neuphoria Therapeutics is a mid-sized biotechnology company focused on developing innovative therapies for neurological disorders. Their competitive advantage lies in their novel drug candidates and strategic partnerships.
Total Addressable Market (TAM)
The TAM for neurological disorder treatments is estimated at $100 billion USD annually. Neuphoria Therapeutics is positioned to capture a significant portion of this market with its innovative therapies. It is estimated Neuphoria can secure at least 5%.
Upturn SWOT Analysis
Strengths
- Innovative drug pipeline
- Experienced management team
- Strong partnerships
- FDA approved anxiety treatment
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on successful clinical trial outcomes
- Relatively small commercial presence
Opportunities
- Expanding into new neurological indications
- Acquiring smaller biotechnology companies
- Securing additional funding through grants and venture capital
- Further strategic partnerships
Threats
- Clinical trial failures
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Patent expirations
Competitors and Market Share
Key Competitors
- PFE
- BIIB
- LLY
- ABBV
Competitive Landscape
Neuphoria Therapeutics faces stiff competition from larger pharmaceutical companies, but their innovative drug pipeline and strategic partnerships provide a competitive edge.
Major Acquisitions
Synapse Biotech
- Year: 2022
- Acquisition Price (USD millions): 250
- Strategic Rationale: Acquired Synapse Biotech to expand its research capabilities and access new drug candidates.
Growth Trajectory and Initiatives
Historical Growth: The company has experienced rapid revenue growth in recent years, driven by the commercialization of Anxiety-Ease.
Future Projections: Analysts project continued revenue growth and improved profitability over the next five years. Estimated 5 year growth rate is 20%.
Recent Initiatives: Recent initiatives include expanding the sales force, launching new marketing campaigns, and investing in research and development.
Summary
Neuphoria Therapeutics shows promise in a demanding industry. Its drug pipeline and strong partnerships position it for future growth. Financial performance has improved as the company has commercialized some of its products. It needs to carefully manage its financial resources and maintain its focus on R&D, watch out for competitive pressure, and regulatory hurdles.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Fictional data based on industry trends and analysis.
Disclaimers:
This analysis is based on fictional data and should not be used for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Neuphoria Therapeutics Inc
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 2024-12-23 | CEO, President & Director Dr. Spyridon Papapetropoulos M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.neuphoriatx.com |
Full time employees 8 | Website https://www.neuphoriatx.com | ||
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7, which is in phase 3 clinical trial for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders; and Nav1.7/1.8 inhibitors which is in preclinical trial for the potential treatment of chronic pain without the liability of addiction associated with opioid treatment. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.